INTRODUCTION {#s1}
============

Head and neck squamous cell carcinoma (HNSCC) is the 6^th^ most common cancer worldwide and affects over 60,000 patients annually in the US \[[@R1]\]. Treatment of advanced HNSCC requires complex, multimodality therapy, employing either definitive radiation with or without chemotherapy or surgical resection and post-operative radiation, with chemotherapy for patients with high-risk of recurrence \[[@R2], [@R3]\]. Currently, there are no molecular biomarkers to guide these management decisions. Multiple studies have demonstrated *TP53* mutations are prognostic for poor outcomes in HNSCC, yet molecular testing for *TP53* alterations has not become routine \[[@R4]--[@R8]\]. Our previous work developed and validated a novel method, EAp53, which can stratify patients with tumors harboring *TP53* mutations as low or high risk which is an extension of the Evolutionary Trace (ET) approach, an extensively validated method to identify key functional or structural residues in proteins \[[@R9]\]. In an effort to predict which *TP53* mutations are highly deleterious every sequence position is assigned a grade of functional sensitivity to sequence variations, defined by whether its evolutionary substitutions correlate with larger or smaller phylogenetic divergences. Residues with large ET grades typically cluster structurally into evolutionary 'hot-spots' that overlap and predict functional sites \[[@R10]\].

We have demonstrated that the ET method could assess the impact of *TP53* missense mutations. The impact was shown to be greater when the mutated residues were more evolutionarily sensitive to sequence variations, i.e. have a larger ET grade, and also when the amino acid change was least conservative, so the mutational impact is the largest. These two components were computed and combined into a single score, called Evolutionary Action EA \[[@R11]\]. To apply this Evolutionary Action to *TP53* mutations in HNSCC, we further developed a scoring system (EAp53) to stratify *TP53* missense mutations into high and low risk. The subset of oncogenic or high-risk p53 mutations was associated with decreased survival in patients with HNSCC and increased cellular invasion and tumorigenicity \[[@R12]\]. In contrast, low-risk p53 mutations appeared to have retained some p53 function since patients with HNSCC containing these alterations had similar survival outcomes to wildtype p53 and cells had an intermediate level of invasiveness and tumorigenicity \[[@R12]\].

Class 2 myosins include a family of three nonmuscle myosins that are implicated in force generation and cell migration \[[@R13], [@R14]\]. Class 2 non-muscle myosins are hexameric molecules, comprised of a pair of heavy chains, a pair of essential light chains, and a pair of regulatory light chains (RLCs). The distinction between the three myosin II molecules is their unique heavy chain isoforms but each functions through the binding and contracting of F-actin in an ATP-dependent manner. *MYH9* encodes the heavy chain of nonmuscle myosin IIA protein (NMIIA). Depletion or inactivation of NMIIA consistently leads to an increase in polarized lamellipodia formation and migration (wound healing) with a concomitant decrease in non-polarized, blunt, cylindrical protrusions or lobopodia (cellular protrusions that share functional attributes with lamellipodia and membrane blebs) formation and focal adhesions \[[@R15]\]. This increase in cell migration following suppression or loss of NMIIA function appears to be due to microtubule stabilization and expansion into lamellae, which can be detected by increased acetylation of α-tubulin in epithelial cells \[[@R16]\]. In NMIIA depleted cells, stabilized microtubules within lamellae may be driving migration through activation of Rac1 leading to enhanced actin polymerization at the leading edge \[[@R16]\]. This mechanism of increased migration through NMIIA suppression can be translated clinically as patients with decreased *MYH9* expression have an associated decrease in overall survival \[[@R17]\]. Therefore, further investigation of NMIIA\'s role in microtubule regulation will be significant by providing the foundation for treatment strategies targeting actively migrating cells.

In addition to NMIIA\'s role in cell migration, it has also been identified as a tumor suppressor that can modulate wildtype p53 (wtp53) expression. The inhibition or suppression of NMIIA leads to decreased p53 nuclear accumulation and subsequent decreases in expression of downstream target genes \[[@R17]\]. To date, whether the tumor suppressor capability of p53 is dependent on the function of NMIIA remains unknown. Furthermore, the tumor suppressor characteristics of NMIIA in the context of mutated p53 have yet to be studied. The phenotypic similarities between high-risk mutp53 and NMIIA depleted cells suggests their common oncogenic phenotype may be due, in part, to loss of NMIIA\'s tumor suppressor function. Therefore, the goal of this study was to determine whether loss of NMIIA function in wtp53 harboring cells reduces its tumor suppressor capability, leading to invasive cell behavior similar to that seen in high-risk mutp53.

RESULTS {#s2}
=======

*MYH9* expression correlates with increased survival in patients with HNSCC having functional p53 {#s2_1}
-------------------------------------------------------------------------------------------------

Our previous work demonstrated in two cohorts totaling 264 patients, the novel EAp53 classification could identify high-risk p53 mutations associated with decreased survival in patients with head and neck cancer \[[@R12]\]. Furthermore, EAp53 identified low-risk p53 mutations that were similar to wildtype p53 and associated with improved survival outcomes and appear to retain some residual p53 function \[[@R12]\]. EAp53 was applied to the p53 sequence data and subsequently integrated with the *MYH9* RNAseq expression data from The Cancer Genome Atlas Network Head and Neck Project (Table [1](#T1){ref-type="table"}) \[[@R18]\]. This analysis revealed patients with low-risk mutp53 and low *MYH9* expression (n=75) had decreased survival outcomes relative to patients with low-risk mutp53 and high *MYH9* expression, *p*=.020 (n=27) (Figure [1A](#F1){ref-type="fig"}). High (n=70) or low (n=20) *MYH9* expression was not prognostic in patients with high-risk p53 mutations (Figure [1B](#F1){ref-type="fig"}).

###### *TP53* mutations scored and stratified by EAp53 with *MYH9* expression data from The Cancer Genome Atlas HNSCC Project

  No.^a^   TCGAID^b^   P53status^c^   Mutation^d^                 EA Score^e^          EA Risk^f^   *MYH9*expression^g^   Lower 25^th^percentile^h^
  -------- ----------- -------------- --------------------------- -------------------- ------------ --------------------- ---------------------------
  1        7250        Wildtype       NA                          0                    Low          19059.1436            Yes
  2        6441        Wildtype       NA                          0                    Low          21185.7003            Yes
  3        6871        Wildtype       NA                          0                    Low          22738.9068            Yes
  4        4730        Wildtype       NA                          0                    Low          23025.1362            Yes
  5        6939        Wildtype       NA                          0                    Low          25580.2255            Yes
  6        4228        Wildtype       NA                          0                    Low          26217.3401            Yes
  7        6938        Wildtype       NA                          0                    Low          30394.2155            Yes
  8        7406        Wildtype       NA                          0                    Low          30611.831             Yes
  9        7440        Wildtype       NA                          0                    Low          32681.4044            Yes
  10       7631        Wildtype       NA                          0                    Low          32909.1267            Yes
  11       7250        Wildtype       NA                          0                    Low          34016.2272            Yes
  12       7261        Wildtype       NA                          0                    Low          34079.456             Yes
  13       7068        Wildtype       NA                          0                    Low          36307.9777            Yes
  14       7406        Wildtype       NA                          0                    Low          38976.1036            No
  15       6954        Wildtype       NA                          0                    Low          39143.3037            No
  16       6492        Wildtype       NA                          0                    Low          39459.7833            No
  17       5243        Wildtype       NA                          0                    Low          40087.7311            No
  18       6939        Wildtype       NA                          0                    Low          41136.5435            No
  19       7632        Wildtype       NA                          0                    Low          41442.4973            No
  20       7410        Wildtype       NA                          0                    Low          41670.6444            No
  21       6938        Wildtype       NA                          0                    Low          42522.8748            No
  22       5247        Wildtype       NA                          0                    Low          42815.4169            No
  23       5625        Wildtype       NA                          0                    Low          42879.4466            No
  24       7774        Wildtype       NA                          0                    Low          43144.2177            No
  25       6955        Wildtype       NA                          0                    Low          44674.5453            No
  26       5325        Wildtype       NA                          0                    Low          45864.7399            No
  27       5355        Wildtype       NA                          0                    Low          49493.0351            No
  28       5149        Wildtype       NA                          0                    Low          50893.2238            No
  29       6227        Wildtype       NA                          0                    Low          52429.5174            No
  30       7429        Wildtype       NA                          0                    Low          52733.2198            No
  31       7373        Wildtype       NA                          0                    Low          53396.9971            No
  32       7261        Wildtype       NA                          0                    Low          54162.1353            No
  33       6010        Wildtype       NA                          0                    Low          54341.1575            No
  34       7407        Wildtype       NA                          0                    Low          54573.2791            No
  35       7392        Wildtype       NA                          0                    Low          55223.3527            No
  36       7832        Wildtype       NA                          0                    Low          56462.9173            No
  37       7427        Wildtype       NA                          0                    Low          61582.7367            No
  38       7367        Wildtype       NA                          0                    Low          61906.8592            No
  39       7395        Wildtype       NA                          0                    Low          63655.5958            No
  40       5369        Wildtype       NA                          0                    Low          64139.3305            No
  41       55565369    Wildtype       NA                          0                    Low          65945.6815            No
  42       74405556    Wildtype       NA                          0                    Low          66238.6672            No
  43       70857440    Wildtype       NA                          0                    Low          73182.8255            No
  44       71837085    Wildtype       NA                          0                    Low          77566.3146            No
  45       71837183    Wildtype       NA                          0                    Low          77566.3146            No
  46       74117183    Wildtype       NA                          0                    Low          85911.796             No
  47       60037411    Wildtype       NA                          0                    Low          91717.6666            No
  48       73976003    Wildtype       NA                          0                    Low          94650.3973            No
  49       74017397    Wildtype       NA                          0                    Low          102414.7452           No
  50       40747401    Mutant         p.E258D                     57.73                Low          14600.1858            Yes
  51       6962        Mutant         p.Y236C                     62.93                Low          20903.5941            Yes
  52       5332        Mutant         p.P151S                     64.12                Low          20955.9877            Yes
  53       6225        Mutant         p.E224D                     39.02                Low          21525.3994            Yes
  54       4076        Mutant         p.Q136P                     71.29                Low          22118.8508            Yes
  55       5329        Mutant         p.R273H                     66.12                Low          22833.8745            Yes
  56       7245        Mutant         p.R282W                     73.21                Low          24809.4695            Yes
  57       5973        Mutant         p.R282W                     73.21                Low          25385.2785            Yes
  58       7424        Mutant         p.E271V                     74.39                Low          25942.2319            Yes
  59       7437        Mutant         p.S106R                     21.82                Low          27579.5418            Yes
  60       7423        Mutant         p.A159V                     62.4                 Low          27604.2023            Yes
  61       6436        Mutant         p.R273H                     66.12                Low          31219.2933            Yes
  62       6962        Mutant         p.Y236C                     62.93                Low          35420.671             Yes
  63       6951        Mutant         p.Y234C                     62.94                Low          35732.5631            Yes
  64       7398        Mutant         p.R337L                     61.55                Low          36115.016             Yes
  65       4736        Mutant         p.I195T                     72.13                Low          37253.7068            No
  66       4740        Mutant         p.M237I                     63.68                Low          37284.3268            No
  67       6933        Mutant         p.P151H                     71.97                Low          38325.6981            No
  68       7238        Mutant         p.R273H                     66.12                Low          39422.9096            No
  69       7592        Mutant         p.Y220C, p.R110L            72.52, 28.14         Low          39492.7307            No
  70       7630        Mutant         p.139_142KTCP\>T, p.M1V     43.89                Low          40807.4754            No
  71       5430        Mutant         p.R282W, p.P89fs            73.21,               Low          41157.1652            No
  72       7424        Mutant         p.E271V                     74.39                Low          41401.4767            No
  73       7437        Mutant         p.S106R                     21.82                Low          43367.2117            No
  74       4739        Mutant         p.R337C                     63.66                Low          44781.6908            No
  75       5151        Mutant         p.V143M                     51.72                Low          44811.7412            No
  76       4217        Mutant         p.R158L                     57.61                Low          44929.7646            No
  77       7238        Mutant         p.R273H                     66.12                Low          44945.2333            No
  78       5978        Mutant         p.V172F                     65.55                Low          45299.2832            No
  79       7414        Mutant         p.E285K                     69.87                Low          47003.5151            No
  80       7235        Mutant         p.F270C, p.T211I            66.32, 68.48         Low          47573.0464            No
  81       6013        Mutant         p.R282W                     73.21                Low          48053.8936            No
  82       7374        Mutant         p.R273H                     66.12                Low          49671.3671            No
  83       7099        Mutant         p.E285K                     69.87                Low          49963.8243            No
  84       5434        Mutant         p.Y236C, p.R213\*           62.93                Low          53941.7304            No
  85       4737        Mutant         p.H168L                     62.62                Low          54291.7232            No
  86       7235        Mutant         p.F270C, p.T211I            66.32, 68.48         Low          54443.1599            No
  87       5334        Mutant         p.S166\*, p.R158H           43.94                Low          55111.0587            No
  88       7089        Mutant         p.Y163C                     70                   Low          60442.0202            No
  89       6933        Mutant         p.P151H                     71.97                Low          62108.8343            No
  90       7394        Mutant         p.R273H                     66.12                Low          64876.995             No
  91       5629        Mutant         p.V157F                     55.26                Low          66941.442             No
  92       7423        Mutant         p.A159V                     62.4                 Low          67549.236             No
  93       5366        Mutant         p.P151T                     70.26                Low          71424.9734            No
  94       7435        Mutant         p.Y220C                     72.52                Low          72632.5124            No
  95       7380        Mutant         p.R282W                     73.21                Low          77702.8389            No
  96       7588        Mutant         p.L137Q                     64.66                Low          80069.0459            No
  97       4733        Mutant         p.R273H                     66.12                Low          80139.2593            No
  98       7236        Mutant         p.V143M                     51.72                Low          85991.952             No
  99       7365        Mutant         p.V216M                     73.3                 Low          87008.6792            No
  100      6221        Mutant         p.V272M                     63.49                Low          98089.8266            No
  101      7245        Mutant         p.R282W                     73.21                Low          112385.1618           No
  102      7090        Mutant         p.R273H                     66.12                Low          128727.6925           No
  103      5370        Mutant         p.R175H, p.Y126_splice      78.51,               High         17991.2352            Yes
  104      6023        Mutant         p.G245S                     86.45                High         20435.1948            Yes
  105      7178        Mutant         p.C176Y, p.R110L            93.11, 28.14         High         22902.4691            Yes
  106      5152        Mutant         p.G245S                     86.45                High         24189.1074            Yes
  107      6943        Mutant         p.R248W                     84.11                High         24203.8835            Yes
  108      7065        Mutant         p.H179P                     98.89                High         24548.4018            Yes
  109      6934        Mutant         p.Y205C                     77.88                High         24737.1678            Yes
  110      7242        Mutant         p.V173M                     75.53                High         25359.3433            Yes
  111      7254        Mutant         p.E258A                     93.29                High         26404.9051            Yes
  112      6959        Mutant         p.R248W                     84.11                High         26977.7238            Yes
  113      7418        Mutant         p.H179Y                     77.78                High         29714.3994            Yes
  114      7370        Mutant         p.C238S                     86.53                High         31748.1805            Yes
  115      6869        Mutant         p.C238F, p.R156P            96.54, 42.93         High         31750.7152            Yes
  116      7399        Mutant         p.P278S, p.R213L            84.34, 90.71         High         33442.556             Yes
  117      7082        Mutant         p.R248W                     84.11                High         34283.7838            Yes
  118      6936        Mutant         p.V173L                     82.64                High         34347.8836            Yes
  119      6935        Mutant         p.C242S                     86.74                High         34914.732             Yes
  120      7848        Mutant         p.E286V, p.P58fs            94.09                High         35968.0861            Yes
  121      7413        Mutant         p.G105C                     90.8                 High         36065.8762            Yes
  122      7263        Mutant         p.Y126C                     81.09                High         36794.0111            Yes
  123      5558        Mutant         p.R282W, p.R175H            73.21, 78.51         High         39755.88              No
  124      6992        Mutant         p.Q331H, p.R249M, p.G245D   9.79, 95.41, 89.56   High         40108.2414            No
  125      6870        Mutant         p.C242Y                     93.46                High         40158.9134            No
  126      5444        Mutant         p.R248Q, p.G245S            78.95, 86.45         High         40765.04              No
  127      6936        Mutant         p.V173L                     82.64                High         41410.0741            No
  128      7242        Mutant         p.V173M                     75.53                High         41666.9217            No
  129      7248        Mutant         p.C242F                     97.04                High         43282.1983            No
  130      6945        Mutant         p.H193L                     95.4                 High         43425.0326            No
  131      5431        Mutant         p.H193P, p.H179Y            92.46, 77.78         High         43788.9126            No
  132      4725        Mutant         p.C275F                     97.06                High         44576.836             No
  133      6872        Mutant         p.R175H                     78.51                High         45312.0393            No
  134      6493        Mutant         p.C229fs, p.S127Y           87.62                High         45516.3524            No
  135      7371        Mutant         p.R175H                     78.51                High         45522.7596            No
  136      5373        Mutant         p.G245V                     98.74                High         45758.6207            No
  137      7402        Mutant         p.R267P                     88.48                High         45787.4794            No
  138      6824        Mutant         p.K132N                     92.16                High         45810.6559            No
  139      6478        Mutant         p.H179R                     81.91                High         45909.8192            No
  140      7368        Mutant         p.R248Q                     78.95                High         46323.4255            No
  141      6935        Mutant         p.C242S                     86.74                High         46893.4093            No
  142      5331        Mutant         p.A307_splice, p.R280T      96.08                High         47291.6078            No
  143      7416        Mutant         p.R248Q                     78.95                High         47571.3318            No
  144      7415        Mutant         p.M133K                     93.62                High         47578.0949            No
  145      4729        Mutant         p.H179R, p.V157F            81.91, 55.26         High         48687.3857            No
  146      5966        Mutant         p.V173M                     75.53                High         49092.3772            No
  147      6218        Mutant         p.V218G, p.L194fs           89.92                High         49304.6974            No
  148      7388        Mutant         p.R273C                     84.52                High         49483.4242            No
  149      7379        Mutant         p.G262V, p.Q136H            88.02, 47.50         High         49736.8282            No
  150      6952        Mutant         p.C275F                     97.06                High         49779.8418            No
  151      5631        Mutant         p.E336\*, p.G245S           86.45                High         50265.4975            No
  152      6012        Mutant         p.Y126S                     94.81                High         50330.1475            No
  153      6020        Mutant         p.C176S                     86.9                 High         51044.6781            No
  154      4723        Mutant         p.C242F                     97.04                High         52741.6378            No
  155      7376        Mutant         p.R280S, p.L32_splice       94.74                High         52830.2812            No
  156      5436        Mutant         p.G266E, p.E56\*            93.08                High         53609.38              No
  157      6024        Mutant         p.L265R                     84.18                High         54654.3939            No
  158      7416        Mutant         p.R248Q                     78.95                High         55950.4367            No
  159      7372        Mutant         p.R248W                     84.11                High         56103.6943            No
  160      7219        Mutant         p.R196P                     95.55                High         59325.7308            No
  161      6011        Mutant         p.P278S, p.Y205fs           84.34                High         59562.9966            No
  162      5365        Mutant         p.H193L                     95.4                 High         59633.7932            No
  163      6491        Mutant         p.M237V, p.H179R            75.79, 81.91         High         61669.9501            No
  164      6516        Mutant         p.G262V                     88.02                High         61964.9147            No
  165      6022        Mutant         p.S261_splice, p.R248W      84.11                High         62102.963             No
  166      4738        Mutant         p.Q331\*, p.H179Y           77.78                High         62189.1787            No
  167      6220        Mutant         p.R280G                     95.71                High         62341.3455            No
  168      5367        Mutant         p.R273C, p.A161T            84.52, 58.51         High         62735.4238            No
  169      7178        Mutant         p.C176Y, p.R110L            93.11, 28.14         High         64539.6273            No
  170      7229        Mutant         p.R249S                     93.65                High         65436.9925            No
  171      5976        Mutant         p.Y236D                     92.17                High         70703.2873            No
  172      6018        Mutant         p.R248W                     84.11                High         70937.0085            No
  173      5970        Mutant         p.R248Q                     78.95                High         75136.8374            No
  174      5330        Mutant         p.G266R                     91.41                High         77750.4254            No
  175      6517        Mutant         p.S127F                     88.07                High         83366.1651            No
  176      6943        Mutant         p.R248W                     84.11                High         83366.6878            No
  177      7102        Mutant         p.G266E                     93.08                High         84155.9398            No
  178      7421        Mutant         p.R175H                     78.51                High         84446.3616            No
  179      5979        Mutant         p.R248Q                     78.95                High         84769.3762            No
  180      6994        Mutant         p.R283P, p.R175H            75.75, 78.51         High         85123.8984            No
  181      6934        Mutant         p.Y205C                     77.88                High         85532.0304            No
  182      6224        Mutant         p.R175H                     78.51                High         86128.7828            No
  183      6959        Mutant         p.R248W                     84.11                High         86287.8985            No
  184      6873        Mutant         p.H193L, p.PHHERC177del     95.4                 High         87361.6071            No
  185      6016        Mutant         p.G245S                     86.45                High         89802.686             No
  186      6826        Mutant         p.V173G                     93.47                High         95987.892             No
  187      6868        Mutant         p.L194P                     79.72                High         98740.1575            No
  188      5555        Mutant         p.H193R                     85.96                High         103716.6397           No
  189      7389        Mutant         p.P278S                     84.34                High         104961.0553           No
  190      5326        Mutant         p.R249S, p.L32_splice       93.65                High         107124.1051           No
  191      7753        Mutant         p.E286K                     76.21                High         118776.7221           No
  192      6474        Mutant         p.G245V                     98.74                High         152088.3031           No

a. The number of patients included in the analysis

b. The short ID extracted from The Cancer Genome Atlas Head and Neck Project

c. P53 status delineated as either wildtype or mutant

d. Denotes the specific mutation for each patient, wildtype is delineated as NA

e. Evolutionary Action score from 0-100 with higher scores representing more deleterious mutations. Wildtype p53 (wtp53) sequences were scored as zero since this is the normally functioning protein.

f. Evolutionary Action Risk was determined as previously described but a score greater than 77.78 was consider high-risk \[[@R12]\].

g. Level of *MYH9* expression extracted from The Cancer Genome Atlas Head and Neck Project RNA seq data

h. Low *MYH9* expression was defined as the lower 25^th^ percentile while high *MYH9* expression was defined as greater the 25^th^ percentile.

![Impact of *MYH9* expression and p53 mutational status\
**A**. Patients with low-risk (functional) p53 mutations and *MYH9* expression in the lower quartile (\<25%) have decreased survival relative to patients with high *MYH9* expression (\>25%). **B**. The expression level of *MYH9* did not impact the survival of patients with high-risk (oncogenic) p53 mutations.](oncotarget-08-22991-g001){#F1}

P53 function is dependent upon a functional NMIIA {#s2_2}
-------------------------------------------------

Using the isogenic HNSCC cell lines, HN30 and HN31, which endogenously express either wtp53 (HN30) or missense p53 mutations, C176F and A161S, (HN31), HN30 was shown to upregulate expression of downstream p53 targets *CDKN1A* (*p21*) and *MDM2* following treatment with nutlin-3; which inhibits the interaction between mdm2 and wild type p53, therefore stabilizing and leading to increased levels of the p53 protein. This target gene upregulation is not observed with the mutp53 cell line, HN31 (Figure [2A](#F2){ref-type="fig"}). NMIIA has been shown to be essential for nuclear retention of activated p53 therefore to determine the impact of NMIIA function on the upregulation of target gene expression observed in the wtp53 cells, the selective, small molecule NMIIA ATPase inhibitor, blebbistatin was applied prior to activation of p53 with nutlin-3. NMIIA inhibition led to a significant reduction in expression of target genes *p21* (*p*=.02) and *MDM2* (*p*=.04) in wtp53, HN30 cells, which was not observed in HN31 cells harboring high-risk mutations (Figure [2A](#F2){ref-type="fig"}). Inhibiting the nuclear export transporter Crm1 restored target gene expression in wtp53 expressing cells, which was not observed in high-risk mutp53 (Figure [2B](#F2){ref-type="fig"}). Taken together this data implies with NMIIA is defective, wtp53 cannot activate target genes because of an inability to accumulate within the nucleus.

![NMIIA is necessary for wtp53 function, which is lost in high-risk mutp53\
**A**. After treatment with DMSO, blebbistatin, or a combination of DMSO + nutlin (D+N) or blebbistatin + nutlin (B+N), qRT-PCR revealed the induction of p53 target genes *p21* (*p* = 0.02) and *MDM2* (*p* = 0.04) were significantly reduced following blebbistatin treatment in HN30 cells but not in HN31 cells. **B**. Inhibition of Crm1 nuclear exporter with Leptomycin B rescued p53 target gene expression in HN30 cells. Data expressed as means ± standard deviation; n=3. \* *p*\<0.05 reduction in *p21* and *MDM2* expression following blebbistatin treatment.](oncotarget-08-22991-g002){#F2}

In an effort to directly assess the impact of NMIIA function on cell invasion, a CMV-GFP-NMII-A plasmid was stably overexpressed in HN30 and HN31 cell lines resulting in a \~50% increase in NMIIA expression in both cell lines (Figure [3](#F3){ref-type="fig"}) \[[@R19]\]. Even this modest (\<2 fold) NMIIA overexpression preferentially decreased invasion in cells harboring wtp53 (*p*=.02) which was not observed in the mutp53 cells (Figure [4A](#F4){ref-type="fig"}). In contrast, inhibition of NMIIA led to an increase in cellular invasion in wtp53 expressing HN30 cells (*p=*.001) but not high-risk mutp53 HN31 cells (Figure [4B](#F4){ref-type="fig"}). Taken together this data suggests the function of wildtype p53 as a transcription factor and regulating cell invasion is dependent on a functional NMIIA.

![Western blot of cell lines stably expressing EGFP-NMIIA construct\
The histogram represents average relative density of NMIIA protein expression compared to actin loading controls and is the results of three independent experiments. EV:empty vector; M9:EGFP-NMIIA vector.](oncotarget-08-22991-g003){#F3}

![Modulation of NMIIA expression or function alters wtp53 expressing cell invasion\
**A**. Forced NMIIA expression significantly reduced invasion in HN30 (wtp53) but not HN31 (high-risk mutp53) cells relative to vector controls, *p*=0.02.EV: empty vector control. **B**. NMIIA inhibition significantly increased invasion in HN30 but not HN31 cells, *p*=0.001.](oncotarget-08-22991-g004){#F4}

Inhibition of NMIIA alters wtp53 but not mutp53 function and cellular localization {#s2_3}
----------------------------------------------------------------------------------

Differences in NMIIA\'s effect on wtp53 *vs*. mutp53 remain unknown \[[@R17]\]. To determine if the selective effect of NMIIA on wtp53 is due to its role in nuclear retention of activated wtp53 but not mutp53, cell fractionation was utilized. The initial fractionation experiment isolated insoluble cellular components (nuclear and cytoskeletal) from soluble cellular components (cytosol). As shown in Figure [5A](#F5){ref-type="fig"} (red boxed lane) following a dual nutlin-3 / blebbistatin treatment a decrease in nuclear / cytoskeletal expression of wtp53 and reduced induction of p21 was observed. The same treatment in mutp53 cells had no effect on the nuclear / cytoskeletal fraction of p53 or target gene induction (Figure [5](#F5){ref-type="fig"}). To assess if NMIIA specifically effects the nuclear retention of wtp53, the nuclear export receptor Crm1 was inhibited which resulted in the restoration of p53 nuclear accumulation (Figure [5B](#F5){ref-type="fig"}, boxed blue lane). To validate these findings a second fractionation protocol was utilized that specifically extracts the nuclear fraction from the cytoskeletal and cytoplasmic fractions. As seen in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}, inhibition of NMIIA following nutlin treatment significantly reduced the nuclear accumulation of wtp53 and p21 induction ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). Furthermore, this decrease in nuclear p21 induction following combined nutlin-3 / blebbistatin treatement inhibition was associated with an significant increase in cytosolic p21 induction ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). To confirm these findings immunofluorescent staining of intact cells following nutlin-3 treatment was performed. As shown in Figure [6](#F6){ref-type="fig"}, we observed a significant increase in co-localization of wtp53 and NMIIA in HN30 cells following nutlin treatment (*p*\<.001) as determined by Pearson\'s correlation coefficient (Figure [6B](#F6){ref-type="fig"}) and depicted by the yellow staining in the representative confocal images of nutlin treated HN30 cells (Figure [6A](#F6){ref-type="fig"}). Furthermore, in blebbistatin treated cells co-localization of wtp53 and NMIIA was attenuated. To determine if the wtp53 / NMIIA co-localization was occurring within the nucleus, the relative fluorescence for individual cells was determined and the average fluorescence for p53 and NMIIA was quantified in the cytoplasm and nucleus (2 and 7 microns from the cell membrane edge respectively (Figure [6A](#F6){ref-type="fig"}). Additionally orthogonal images were constructed from Z stack image capture through the depth of each cell. These analyses revealed that following nutlin-3 treatment, wtp53 and NMIIA appear to co-localize within the nucleus, which is attenuated following blebbistatin treatment supporting the finding that nuclear retention of wtp53 requires a functional NMIIA (Figure [6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"} column B+N). While co-localizatiohn of NMIIA and mutp53 was also observed it appeared to be independent of p53 and NMIIA activity given that treatment with either nutlin-3 or blebbistatin did not alter their co-localization.

![Inhibition of NMIIA alters wtp53 but not high-risk mutp53 cellular localization\
**A**. Nutlin-induced nuclear / cytoskeletal p53 and p21 was detected in HN30 (wtp53) cells. Blebbistatin treatment attenuated the effect of nutlin on nuclear p53 and p21 induction (red box). **B**. Average relative density in the nuclear / cytoskeletal and cytosolic fractions normalized the level of p53 and p21 to Lamin B and BCAR3 respectively. This revealed a significant increase in p53 and p21 after nutlin treatment relative to control (\* *p*=.010), along with a significant decrease in p53 and p21 after blebbistatin relative to control (§ *p*=.032). **C**. Nuclear accumulation of p53 was restored by leptomycin B (Lept B) treatment. **D**. Average relative density in the nuclear / cytoskeletal and cytosolic fractions normalized the level of p53 to Lamin B and BCAR3 respectively. The expression levels of p53 in HN31 (mutp53) cells was unaffected by nutlin, blebbistatin, or leptomycin B treatment. The histograms represent the cumulative results of three independent experiments.](oncotarget-08-22991-g005){#F5}

![NMIIA co-localization with wtp53 is attenuated following NMIIA inhibition\
**A**. Representative confocal fluorescence images including Z stack generated orthogonal views (xzy) showed the colocalization of wtp53 and NMIIA in HN30 cells not seen in high-risk HN31 cells (mutp53). The relative immunofluorescence profile revealed a significant increase in nuclear colocalization of p53 / NMIIA following nutlin treatment (*p*\<0.001) which is attenuated following NMIIA inhibition. **B**. Data summary shows colocalization efficiency of NMIIA and p53. Nutlin treatment (D+N) caused a significant increase in colocalization in HN30 (p\<0.001) but not HN31 (p=0.179) cells. There was a significant reduction in colocalization in HN30 cells following blebbistatin treatment (B+N) not observed in HN31 cells (p=0.019 vs .25). Data expressed as means +/− SEM; n=3. \* p\<.05 versus DMSO control group; § p\<0.05 (DMSO + nutlin versus blebbistatin + nutlin). D+N, DMSO +nutlin; B+N, blebbistatin + nutlin.](oncotarget-08-22991-g006){#F6}

To confirm the nuclear co-localization of wtp53 and NMIIA, cell fractionation followed by direct co-immunoprecipitation from these fractions was performed. This approach revealed an increase in wtp53/NMIIA association in the nuclear / cytoskeletal fraction along with a concomitant decrease in cytosolic interaction following nutlin treatment (Figure [7](#F7){ref-type="fig"} blue box lanes). The nuclear / cytoskeletal association of wtp53 / NMIIA was reduced in cells treated with blebbistatin (Figure [7](#F7){ref-type="fig"} red boxed lane). As observed by immunofluorescence microscopy, there appears to be an association of mutp53 / NMIIA based on co-immunoprecipitation, but this interaction remained at basal levels following addition of nutlin and/or combined treatment with blebbistatin.

![NMIIA exhibits increased interaction with wtp53 in the nucleus\
HN30 and HN31 cells were treated with blebbistatin (Blebb) or control (PBS) followed by nutlin for 8 h. Cells were fractionated followed by co-immunoprecipitation:immunoblot analysis of NMIIA and p53. **A**. Following p53 activation with nutlin there was a significant increase in association between wtp53 / NMIIA in the nuclear / cytoskeletal fraction of HN30 cells and a concomitant decrease in association in the cytosolic fraction, p\<.001 and 0.01, respectively (Blue highlight). The increased association in the nuclear / cytoskeletal fraction was significantly reduced by blebbistatin, p=0.02 (Red highlight). Neither nutlin or blebbistatin treatment had an effect on the nuclear / cytoskeletal or cytosolic mutp53/NMIIA interaction. **B**. Average relative density normalizes the level p53 to NMIIA. The histograms represent the results of three independent experiments. \* Significant change in interaction after nutlin treatment relative to control. § Significant decrease in p53/NMIIA interaction after blebbistatin relative to nutlin.](oncotarget-08-22991-g007){#F7}

DISCUSSION {#s3}
==========

*TP53* is the most frequently mutated gene in HNSCC occurring in more than 70% of cases that are non-human papilloma virus related \[[@R18], [@R20], [@R21]\]. Whereas most alterations involving tumor suppressor genes render them nonfunctional through truncation or deletions, p53 is unique in that there is a strong selection bias for missense mutations, particularly within its DNA-binding domain. P53 mutation can result in loss of wild type functions (LOF), which are considered low-risk, through loss of DNA-binding activity to p53 responsive elements or a dominant negative effect where the mutated allele binds and inhibits the remaining functional wild-type allele \[[@R22]\]. Moreover, some mutp53 display oncogenic properties, termed "gain of function" (GOF) or high-risk mutations, which are independent of the loss of wild-type p53 function \[[@R23]\]. Accordingly, GOF p53 mutants can enhance cell transformation, increase tumor formation in mice and confer cellular resistance to chemotherapy \[[@R24], [@R25]\]. We previously developed and validated a novel method, EAp53 that stratifies patients with tumors harboring *TP53* mutations as high or low risk. Although the underlying mechanisms responsible for high-risk mutp53 remain unresolved, a potential mechanism involves interaction with NMIIA. In addition to the critical role NMIIA has in cell contractility and migration, it also functions as a tumor suppressor through regulation of p53 stability and nuclear retention \[[@R15]--[@R17], [@R26]\]. Despite this novel finding, there continues to be a significant gap in the understanding of the impact of NMIIA on mutp53 and its ability to function as a tumor suppressor and/or contribute to the oncogenic phenotype of p53. Given this lack of understanding, the objective of this study was to correlate the tumor suppressor effects of p53 with NMIIA function and demonstrate NMIIA dysfunction in cells harboring wildtype p53 results in characteristics resembling high-risk mutp53 including increased invasion. We hypothesized that the tumor suppressor capability of p53 is dependent on NMIIA function, which when abrogated leads to an oncogenic phenotype of p53 that is similar to high-risk mutp53.

Our results show patients stratified by EAp53 with low-risk mutp53 had a decreased overall survival with low *MYH9* expression relative to those patients with low-risk mutp53 and high *MYH9* expression. In contrast, the relative expression of *MYH9* did not impact survival in patients with high-risk mutp53. Our previous work demonstrated low-risk *TP53* mutations appear to retain some residual wildtype *TP53* function as demonstrated by an intermediate level of activation of downstream p53 target genes following treatment with cisplatin \[[@R27]\]. Furthermore, this intermediate activation was associated with decreased cell migration and tumor growth in animal models \[[@R12]\]. Taken together, these data indicate that the tumor suppressive capability of NMIIA appears to be confined to tumor cells with functional *TP53*.

In addition to identifying the potential prognostic significance of *MYH9* expression in low-risk mutp53 disease, we demonstrated inhibition of NMIIA leads to increased invasion in wtp53 expressing cells but not in high-risk mutp53 expressing cells. Furthermore, overexpression of NMIIA reduced invasion only in cells expressing wildtype p53. These findings corroborate a previous study and support our hypothesis that the tumor suppressor capability of p53 is dependent on NMIIA function \[[@R17]\]. This hypothesis is further supported by the finding of reduced p53 target gene expression in wildtype p53 cells following NMIIA inhibition, which was not observed in high-risk mutp53. The ability of wildtype p53 to activate downstream target genes appears to be dependent on nuclear localization of p53 as the reduction of target gene expression following NMIIA inhibition could be reversed with nuclear export inhibition. Furthermore, cell fractionation studies revealed induction of p53 and p21 in the nuclear fraction by nutlin treatment of wtp53 cells can be attenuated with blebbistatin treatment. The decrease in nuclear p21 induction was associated with a concomitant increase in the cytosolic p21 level which has been associated with increased cell survival and proliferation \[[@R28]\] This reduction in p53 induction in wtp53 cells with inhibition of the NMIIA ATPase can be reversed with Crm1 inhibition, which supports published data \[[@R17]\]. In contrast, inhibition of NMIIA did not alter expression of p21 or MDM2 in mutp53 cells or retention of mutp53 within the nucleus.

These findings are supported by immunofluorescence microscopy demonstrating an increase in the co-localization of wtp53 and NMIIA following nutlin treatment, which was subsequently reduced by NMIIA inhibition. Colocalization was predominantly nuclear as demonstrated by the Z stack generated orthogonal views and the relative cellular immunofluorescence, which was confirmed by cell fractionation:immmunoprecipitation findings. Although mutp53 and NMIIA appeared to co-localize, this was independent of NMIIA ATPase activity and was observed diffusely throughout the cell based on microscopy and supported by cell fractionation data.

In conclusion, the current findings indicate that cells expressing wtp53 are dependent on NMIIA inhibition to become pro-invasive secondary to decreased nuclear accumulation of wtp53 and subsequent reduction in target gene expression. In contrast, cells harboring high-risk mutp53 attain an invasive phenotype independent of NMIIA.

MATERIALS AND METHODS {#s4}
=====================

Patient data {#s4_1}
------------

Patient dataset from The Cancer Genome Atlas HNSCC Project that had human papilloma virus (HPV)-negative tumors (n=192) were identified and EAp53 was applied to the p53 sequence data \[[@R12], [@R18]\]. *MYH9* RNAseq expression data from The Cancer Genome Atlas Network Head and Neck Project was subsequently integrated with the p53 sequence data. *MYH9* expression less than or equal to the lower quartile (≤25 percentile) for the entire cohort was considered to be low expression while expression greater than the lower quartile (\>25 quartile) was considered to be high expression (Table [1](#T1){ref-type="table"}). Overall survival data was extracted from TCGA HNSCC [Supplementary Data](#SD1){ref-type="supplementary-material"}. Curves describing overall survival were generated by the Kaplan-Meier method. The statistical significance of differences between the actuarial curves were assessed by the log rank test. Overall survival was measured from the date of diagnosis of recurrent disease to the date of death or last contact. Statistical analyses were performed using GraphPad Prism 7.0e (GraphPad Software, Inc., La Jolla, CA) statistical software.

Cell culture {#s4_2}
------------

The isogenic HNSCC cell lines HN30 and HN31 (provided by Dr. John Ensley; Wayne State University) were chosen as they were derived from a pharyngeal primary tumor and lymph node from the same patient. HN30 harbours a wtp53 while HN31 harbours two p53 mutations, C176F (high-risk) and A161S (low-risk). HN30 and HN31 cells were grown in DMEM with high glucose containing 10% FBS, 0.5% penicillin and streptomycin, 2 mM L-glutamine, 1 mM Sodium pyruvate, 85 mg/mL NaCl, 1 mg/mL D-calcium pantothenate, 1 mg/mL choline chloride, 1 mg/mL folic acid, 2 mg/mL i-inositol, 1 mg/mL niacinamide, 1 mg/mL pyridoxine- HCl, 0.1 mg/mL riboflavin, 1 mg/mL thiamine - HCl and non essential amino acids including 0.1 mM glycine, 0.1 mM alanine, 0.1 mM asparagine, 0.1 mM aspartic acid, 0.1 mM glutamic acid, 0.1 mM proline, 0.1 mM serine. The cells were maintained in a 37°C incubator with 95% air and 5% CO~2~

Drug incubation {#s4_3}
---------------

HN30 and HN31 cells were growth arrested in serum-free medium for 24 hrs prior to drug treatment. Cells were pretreated with DMSO or 25 μM blebbistatin (Cayman Chemicals 674289-55-5) for 30 min prior to 8 hrs of treatment with 5 μM of nutlin-3 (Sigma-Aldrich N6287). For some Western blot analyses, (where indicated), 20 nM of leptomycin (Cayman Chemical 87081-35-4) was added 30 min prior to pretreatment of cells with DMSO or blebbistatin.

qRT-PCR {#s4_4}
-------

RNA was prepared from HN30 and HN31 cells using High Pure RNA Isolation Kit (Roche Diagnostics). cDNA was synthesized from RNA using iScript cDNA Syntheis Kit (Bio-Rad). The amplified cDNA was used in quantitative real-time PCR using SYBR Green PCR Master Mix (Applied Biosytems). The primer pairs used for analyzing *p21*, *MDM2*, and *GAPDH* were previously published \[[@R27]\]. The primer pairs used were as followed: p21 forward 5′-CGCTAATGGCGGGCTG-3′, reverse 5′-CGGTGACAAAGTCGAAGTTCC-3′; MDM2 forward 5′-ACCTCACAGATTCCAGCTTCG-3′, reverse 5′-TTTCATAGTATAAGTGTCTTTTT-3′; GAPDH forward 5′-TGATGGTACATGACAAGGTGC-3′, GA PDH reverse 5′-ACAGTCCATGCCATCACTGC-3′.

Generation of stable cell lines {#s4_5}
-------------------------------

For stable transfections, HN30 and HN31 cells were cultured in 6-well plates until they reached 70-80% confluency. The cells were transfected with CMV-GFP-NMHC II-A (Addgene plasmid \# 11347) using 6 μg of using NanoJuice Transfection Reagent in serum-free medium (Novagen) according to the manufacturer\'s protocol \[[@R19]\]. HN30 and HN31 cells were cultured for 7-14 days in 400 μg/ml of geneticin before being sorted for selection of stable clones.

Invasion assay {#s4_6}
--------------

After stably transfecting HN30 and HN31 cells with vectors, invasion studies were conducted using Corning BioCoat Matrigel Invasion Chambers as described by the manufacturer (Corning). Cells were seeded in Matrigel Basement Membrane Matrix inserts in 24-well plates at a density of 2.5×10^4^ cells per well. After 22 hr in a 37°C incubator, cells were fixed with 3% formalin and stained with silver stain. Membranes were washed and allowed to dry before an image was obtained and the number of invaded cells quantified. For studies that involved drug incubation, HN30 and HN31 cells were plated at a density of 2.5×10^4^ cells in medium containing either DMSO or 25 μM of Blebbistatin.

Cell fractionation and western blot analysis {#s4_7}
--------------------------------------------

For Western blot analysis, HN30 and HN31 cells were grown in 100 mm tissue culture dishes. After treatment with the various drugs described, cells were rinsed and then lysed in cytosolic fractionation buffer (5 mM of EDTA, 1 mM of dithiothreitol, 1% Triton X-100 in PBS) supplemented with protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mM NaF, 1 mM Na~3~VO~3~, 1 μg/ml leupeptin, 1 μg/ml aprotinin, and 1 μg/ml pepstatin). After brief centrifugation the supernatants were collected as the cytosolic extract and the pellets were washed and resuspended in nuclear extraction buffer (20 mM of TRIS-HCl, 1% SDS, 5 mM EGTA, 0.5% Triton X-100, 150 mM of NaCl) supplemented with protease inhibitors.

An alternative fractionation protocol was used where after treatment with the various drugs as described, nuclear and cytoplasmic extracts were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit from ThermoFisher Scientific (Catalog \#: 78833). Equal amounts of protein sample were loaded per lane on Mini-PROTEAN TGX Precast Gels (Bio-RAD) which were transferred to nitrocellulose membranes following electrophoresis. Blots were incubated with primary antibodies to p53 (Santa Cruz Biotechnology sc-126), p21 (EMD Millipore OP64), NMIIA (Santa Cruz Biotechnology sc-98978), BCAR3 (Bethly Laboratories A301-671A), Lamin B (Santa Cruz sc-6216), GFP (Cell Signaling 2956S), actin (Millipore MAB1501) and subsequently reacted with the corresponding secondary antibodies. All secondary antibodies were horseradish peroxidase conjugates. Blots were developed by Enhanced Chemiluminescence Kit (Thermo Scientific) before exposure to X-ray film. Densitometry was performed using FIJI/Image J software and paired t-tests compared the relative intensities using Microsoft Excel (Microsoft Corp, Redmond, WA) \[[@R29]\].

Immunoprecipitation {#s4_8}
-------------------

For NMIIA immunoprecipitation, HN30 and HN31 cells grown in 100 mm tissue culture dishes were fractionated as described above equal amounts of nuclear and cytoplasmic proteins were pre-cleared by incubation with protein A/G Sepharose beads for 30 min at 4°C. After brief centrifugation, supernatants were removed and incubated with anti-Myosin 9 antibody (Santa Cruz Biotechnologies sc-98978) overnight. Immunoprecipitates were captured with 60 μl of protein A/G beads at 4°C for 3 hr. Samples were centrifuged and washed three-fold with PBS and proteins were eluted from the beads using 2x Laemmli buffer, boiled for 5 min, and resolved by SDS-PAGE and subsequent immunoblot analysis with mouse monoclonal antibodies for p53 (Santa Cruz Biotechnologies sc-126) and Myosin 9 (Millipore MABT164). Densitometry and statistical analysis were performed as described above.

Immunofluorescence microscopy {#s4_9}
-----------------------------

Following the drug treatments described above, cells were fixed with 4% paraformaldehyde for 10 min at room temperature, permeabilized with 0.5% Triton X-100 (Sigma) in PBS for 5 min and non-specific binding sites were blocked with 1% BSA in PBS for 1h. Primary and secondary antibodies were diluted in blocking solution as directed by the manufacturer. Antibodies employed were anti-p53 (1:500; Santa Cruz Biotechnology), anti-NMIIA (1:500; Santa Cruz Biotechnology), anti-rabbit Alexa Flour 488 (Life Technologies) anti-mouse Alexa Fluor 546 (Molecular Probes). Confocal microscopy was performed using an Olympus FV10i laser scanning confocal microscope (Olympus, Tokyo, Japan). Colocalization of NMIIA and p53 was analyzed by FIJI/Image J software with the coloq2 plugin \[[@R29]\]. The plot profile for 8 cells per condition was determined and the mean was relative immunofluorescence was calculated. The average cell diameter was estimated to be 14 microns, there the relative immunofluorescence within the cytoplasm and nucleus was measured 2 and 7 microns from the cell membrane respectively. The average relative immunofluorescence following various treatments within the nucleus and cytoplasm was compared using a paired T-test. The summarized colocalization efficiency data were expressed as Pearson correlation coefficients as previously described \[[@R30]\].
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